Donald Trump’s 100% Tariff Tantrum Rattles Sunpharma, Biocon, Lupin & Other Pharma Stocks

Indian pharma faces a major jolt as President Trump slaps 100% tariffs on branded and patented medicines from October. While the move spares companies setting up plants in the US, it puts at risk nearly $1 billion worth of Indian exports. The US, India’s biggest pharma market, buys a third of its drug exports—dominated by low-cost generics that power America’s affordable healthcare.